Diamonds and Dogs
Biogen is back. Biogen (BIIB) is jumping 8% following strong earnings thanks to better than expected sales of its treatment for multiple sclerosis. The company is forecasting 2016 revenue forecast of $11.1 billion to $11.3 billion assumes no price increases for its key multiple sclerosis drugs -- Tecfidera, Avonex, Tysabri and Plegridy. After last year, when biotechs came under fire for their constant price hikes, a price halt for their more popular drugs seems to be a win for patients and shareholders. With the stock down 40% from the 2015 highs now trading for 15 times earnings, Biogen looks like an attractive long term buy.
Flight delay at Boeing. Boeing (BA) is getting hit today down 6%, falling as much as 10% this morning to a new 52 week low after the company lowered guidance for 2016. Boeing cut production by one plane per month for their 747 jumbo-jet. Earnings will now be flat year over year, but the long term bullish case is still intact. Cash flow remains strong jumping to over $10 billion in 2016. With the stock near its 52 week low, the company can now resume thier share buyback plan at prices 15% below December levels. Analysts expect growth to resume in 2017, but unfortunately in the short term, the stock may be stuck on the tarmac for a while.
Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.